Platelet inhibition by abciximab is reduced in patients with the A2 allele of the glycoprotein (GP) IIb/IIIa receptor

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1328, 2002-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platelet Glycoprotein IIb/IIIa Receptor Antagonists And Their Use In Elderly Patients

By Mak K-H.

Drugs & Aging, Vol. 16, Iss. 3, 2000-03 ,pp. : 179-187

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P. Moliterno D.J.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite

Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker

By de Belder M. Sutton A.

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 10, 1998-10 ,pp. : 1701-1717

Informa Healthcare

Access to resources Recommend Favorite

Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions

By Starnes H. Benjamin Patel Ankit A. Stouffer George A.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2009-2030

Adis International

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Current Concepts and Future Directions

By Ferguson J.J. Zaqqa M.

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 965-982

Adis International

Access to resources Recommend Favorite